Stein, Mark N.

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors

Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 543

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies

Stein, M., Lin, H., Jeyamohan, C., Dvorzhinski, D., Gounder, M., Bray, K., Eddy, S., Goodin, S., White, E., & DiPaola, R. S. (2010) · The Prostate

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 291

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 181

Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

De Bono, J. S., Fong, L., Beer, T. M., Gao, X., Geynisman, D. M., Burris III, H. A., Strauss, J. F., Courtney, K. D., Quinn, D. I., VanderWeele, D. J., et al. (2021) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 39

DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).

Parsonson, A. O., Gandhi, C., Henick, B. S., Schmidt, A. L., Ye, D., Amin, H., Wise-Draper, T. M., Courtney, K. D., Tam, L., Jiang, S., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 9